Celanese reports record full year 2022 net sales of $9.7B and GAAP diluted EPS of $17.41

Celanese Corp

2022-FY EPS reported $17.34 revenue$9,673,000,000

Record full year 2022 net sales of $9.7 billion, up 13% from prior record in 2021.
GAAP diluted EPS of $17.41 and adjusted EPS of $15.88 for full year 2022.
Record operating cash flow of $1.8 billion and free cash flow of $1.3 billion in 2022.
Completed acquisition of DuPont's Mobility & Materials business on November 1, 2022.
Q1 2023 adjusted EPS guidance of $1.50 to $1.75, expecting sequential improvement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celanese Corp reported full year 2022 results: revenue $9.7 billion, EPS $17.41.

Period: full year 2022
Revenue: $9.7 billion
EPS: $17.41
Result: reported results

Exact text from the filing

Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today reported highest-ever GAAP diluted earnings per share of $17.41 and second-highest ever adjusted earnings per share of $15.88 for full year 2022. The Company generated record net sales of $9.7 billion in the year, an increase of 13 percent over the prior record set in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celanese Corp reported the fourth quarter 2022 results: EPS $7.03.

Period: the fourth quarter 2022
EPS: $7.03
Result: reported results

Exact text from the filing

Celanese also reported fourth quarter GAAP diluted earnings per share of $7.03 and adjusted earnings per share of $1.44.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Celanese Corp filing history →

Source: SEC EDGAR

accession 0001306830-23-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.